Common Side Effects of Anti-EGFR Therapy: Acneform Rash
作者： Rebecca Sipples
DOI: 10.1016/J.SONCN.2006.01.013
关键词:
摘要: … ,21, 22 although rash is sometimes associated with bacterial or fungal … rash varies slightly with anti-EGFR treatment. Gefitinib-associated skin toxicity most commonly presents as dry skin…
elsevier.com
sci-hub.se 参考文章(27)
Steven Averbuch, Peter Wadsworth, Seiichi Yano, Michael Hutchison, Motonori Yamaguchi, Graham Richmond, Kaoru Kondo, Alan Wakeling, Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Research. ,vol. 23, pp. 3639- 3650 ,(2003)
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904
Kenya Shitara, Yoshihisa Kuwana, Kazuyasu Nakamura, Yuko Tokutake, So Ohta, Hiromasa Miyaji, Mamoru Hasegawa, Nobuo Hanai, A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities Cancer Immunology, Immunotherapy. ,vol. 36, pp. 373- 380 ,(1993) , 10.1007/BF01742253
Roy S. Herbst, Patricia M. LoRusso, Michele Purdom, Deborah Ward, Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management Clinical Lung Cancer. ,vol. 4, pp. 366- 369 ,(2003) , 10.3816/CLC.2003.N.016
Mark A. Lemmon, Joseph Schlessinger, Cell signaling by receptor-tyrosine kinases Cell. ,vol. 141, pp. 1117- 1134 ,(2000) , 10.1016/J.CELL.2010.06.011
A. F. LoBuglio, R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, L. Sun, J. Ghrayeb, M. B. Khazaeli, Mouse/human chimeric monoclonal antibody in man: kinetics and immune response Proceedings of the National Academy of Sciences of the United States of America. ,vol. 86, pp. 4220- 4224 ,(1989) , 10.1073/PNAS.86.11.4220
M NEEDLE, Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody Seminars in Oncology. ,vol. 29, pp. 55- 60 ,(2002) , 10.1016/S0093-7754(02)70091-2
Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark Huberman, Daniel Karp, James Rigas, Gary M. Clark, Pedro Santabárbara, Philip Bonomi, Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3238- 3247 ,(2004) , 10.1200/JCO.2004.11.057